KCC2 Potentiator Compositions for Hard-to-Treat Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics for neurological disorders related to potassium chloride cotransporter-2 (KCC2) are inadequate in reducing suffering and improving recovery, posing severe challenges for patients with neurological disorders such as neurotraumatic, neurodevelopmental, and affective disorders.
Innovation Solution
Development of compounds and pharmaceutical compositions targeting KCC2, including specific chemical structures and their pharmaceutically acceptable salts, for administration to treat or prevent neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutics are used to treat neurological disorders related to KCC2, then some treatment effect is achieved, but the suffering is not adequately reduced and recovery is not sufficiently improved
Solution Approach 1:
The patent modifies the chemical structure of KCC2 potentiators by changing parameters such as substituting hydrogen atoms with halogen atoms (fluorine, chlorine), introducing different side chains, and adjusting molecular weight and lipophilicity. These parameter changes result in compounds with enhanced therapeutic effectiveness and reduced side effects, directly addressing the contradiction between treatment efficacy and patient suffering.
Solution Approach 2:
The patent creates composite molecular structures by combining different functional groups and chemical moieties in novel potentiator compounds. These composite structures enable multi-target engagement and synergistic effects, improving therapeutic outcomes while reducing the harmful effects associated with existing single-mechanism therapeutics.
2Reliability
If existing therapeutics are used to treat neurological disorders related to KCC2, then some treatment effect is achieved, but severe challenges remain for patients
Solution Approach 1:
The patent introduces local quality modifications by placing specific functional groups at particular positions within the molecular structure. For example, adding hydrophilic groups at specific locations can improve bioavailability and reduce off-target effects, thereby improving quality of life while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs dynamic molecular design where certain parts of the molecule can adapt conformationally to bind different targets or interact with biological membranes in flexible ways. This dynamic behavior allows the compounds to achieve effective treatment while having fewer rigid constraints on patient management, improving overall quality of life.
Data Source
AI summary
The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.